TY  - GEN
AU  - Raffi,François
AU  - Babiker,Abdel G
AU  - Richert,Laura
AU  - Molina,Jean-Michel
AU  - George,Elizabeth C
AU  - Antinori,Andrea
AU  - Arribas,Jose R
AU  - Grarup,Jesper
AU  - Hudson,Fleur
AU  - Schwimmer,Christine
AU  - Saillard,Juliette
AU  - Wallet,Cédrick
AU  - Jansson,Per O
AU  - Allavena,Clotilde
AU  - Van Leeuwen,Remko
AU  - Delfraissy,Jean-François
AU  - Vella,Stefano
AU  - Chêne,Geneviève
AU  - Pozniak,Anton
TI  - Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
SN  - 1474-547X
PY  - 2015///0120
KW  - Adenine
KW  - analogs & derivatives
KW  - Adult
KW  - Anti-HIV Agents
KW  - therapeutic use
KW  - CD4 Lymphocyte Count
KW  - Cholesterol, HDL
KW  - metabolism
KW  - Cholesterol, LDL
KW  - Darunavir
KW  - Deoxycytidine
KW  - Drug Resistance, Viral
KW  - Drug Therapy, Combination
KW  - Emtricitabine
KW  - Female
KW  - HIV Infections
KW  - drug therapy
KW  - HIV-1
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Organophosphonates
KW  - Pyrrolidinones
KW  - Raltegravir Potassium
KW  - Ritonavir
KW  - Sulfonamides
KW  - Tenofovir
KW  - Treatment Outcome
N1  - Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S0140-6736(14)61170-3
ER  -